Anti-HIV drugs and the mitochondria  by Pinti, Marcello et al.
Biochimica et Biophysica Acta 1757 (2006) 700–707
http://www.elsevier.com/locate/bbaReview
Anti-HIV drugs and the mitochondria
Marcello Pinti a, Paolo Salomoni b, Andrea Cossarizza a,⁎
a Department of Biomedical Sciences, Section of General Pathology, University of Modena and Reggio Emilia School of Medicine,
via Campi 287, 41100 Modena, Italy
b MRC Toxicology Unit, University of Leicester, Lancaster Rd Box 138, Leicester, LE1 9HN, UK
Received 12 December 2005; received in revised form 2 May 2006; accepted 5 May 2006
Available online 11 May 2006Abstract
Several drugs are currently used that can significantly prolong the course of the infection with the human immunodeficiency virus (HIV), the
cause of the acquired immunodeficiency syndrome (AIDS). Among these drugs, the nucleosidic inhibitors of viral reverse transcriptase can alter
mitochondrial (mt) function by inhibiting the mitochondrial DNA polymerase gamma (the enzyme responsible for the replication of mtDNA).
Decreased mtDNA content provokes a diminished synthesis of respiratory chain enzymes, leading to alterations in mt function. These are in turn
responsible for a variety of side effects frequently observed in HIV+ patients, that range from hyperlactatemia and lactic acidosis to lipodystrophy,
a pathology characterized by accumulation of visceral fat, breast adiposity, cervical fat-pads, hyperlipidemia, insulin resistance and fat wasting in
face and limbs. In this paper, data concerning the effects of different compounds on mitochondria, their role in the pathogenesis of lipodystrophy,
and problems related to studies on the mt toxicity of antiviral drugs are reviewed and thoroughly discussed.
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Potent antiretroviral drugs can prolong for extremely long
periods the course of the infection with the human immunode-
ficiency virus (HIV), the cause of the acquired immunodefi-
ciency syndrome (AIDS). According to the Joint United Nations
Programme on HIV/AIDS (UNAIDS), AIDS has caused the
death of more than 25million people since it was first recognized
in 1981 [1]. It has been estimated that in 2005 alone, deaths due
to AIDS were more than 3 million, among which more than half
amillionwere children. The total number of people infected with
the human immunodeficiency virus (HIV) reaches now its high-
est level, with an estimated number of more than 40 million
persons. Close to 5 million people have been newly infected by
the virus in 2005, and there is no evidence that dissemination of
the infection is decreasing.
Before the use of antiviral drugs, infection with HIV caused an
inexorable decline in immune functions, leading to fatal con-
sequences. Until 10 years ago, the only drugs that had some⁎ Corresponding author. Tel.: +39 059 2055415; fax: +39 059 2055426.
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doi:10.1016/j.bbabio.2006.05.001effects onHIV infection were a few compounds of the category of
nucleosidic reverse transcriptase inhibitors (NRTIs), present in the
pharmacopoeia for decades, that had a weak antineoplastic action
and some antiretroviral efficacy [2]. Other drugs capable of inhi-
biting HIV protease (instead of the viral reverse transcriptase)
were designed in the mid-1990s that have been capable first of
delaying the onset of AIDS, then to stop the progression of the
infection, even for extremely long periods [3]. The ability to
inhibit viral replication is currently achieved in most patients with
the so-called highly active antiretroviral therapy (HAART), a
combination of viral protease inhibitors (PIs) and nucleosidic,
non-nucleosidic or nucleotidic reverse transcriptase inhibitors.
Another category of drugs is now available, such as the inhibitors
of viral entry into the cell [4]. HIV+ patients assuming HAART
survive by keeping the infection dormant, but not by eliminating
the virus altogether. This therapy has indeed increased the quality
of life in HIV+ individuals. Nonetheless, most infected persons
live in countries where treatment is not available or is absolutely
unaffordable at its current price. Furthermore, HAART has se-
rious side effects, of social, economical and clinical importance.
First of all, most infected persons live in countries where treat-
ment is not available or has an unaffordable price. Second, the
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health measures that threaten a recrudescence of epidemic infec-
tion, especially in western countries. Third, antiretroviral drugs
have several side effects, with different incidences and severities,
including myopathy, migraine, dementia, ataxia, stroke-like epi-
sodes, hypertrophic cardiomyopathy, gastrointestinal complaints,
increased bilirubin serum levels, nephrolitiasis, perioral paresthe-
sias, diabetes mellitus, hypoparathyroidism, hypogonadism,
infertility, dysphagia, nausea, vomiting, intestinal pseudo ob-
struction, anemia, pancytopenia, pancreatitis, depression, among
others. Finally, it has been observed that HAART is responsible
for a frequent and devastating side effect such as lipodystrophy, a
syndrome characterized by peripheral fat wasting in face and
limbs, accumulation of visceral fat, breast adiposity, cervical fat-
pads, hyperlipidemia, and insulin resistance [5,6]. Several me-
chanisms are likely involved in the pathogenesis of lipodystrophy,
and some of them are poorly known. However, there is a general
agreement that drugs of the category of nucleosidic reverse tran-
scriptase inhibitors (NRTIs) are the main responsible for fat loss,
since they can alter mitochondrial function, provoke apoptosis,
and induce the elimination of precursors and eventually stem cells
in different tissues [7–9].
2. Mitochondria damage in HIV+ patients
The interactions between HIV, drugs and mitochondria have
been under investigation for several years. In vitro studies on 3′-
azido-3′-deoxythymidine and other dideoxynucleoside analogues
first showed that these molecules can alter mitochondrial (mt)
DNA content by inhibiting polymerase gamma, the enzyme res-
ponsible for the replication of mtDNA [10,11]. Ex vivo studies
were then performed by electron microscopy on portions of
cardiac tissue from patients who died from AIDS, searching for
the presence of the virus [12]. Unexpectedly, it was observed that
cardiac myocytes were characterized by the presence of large
numbers of proliferating multilamellated membrane bodies, pre-
dominantly associated with mitochondria. Subsequently, it was
reported that in zidovudine-treated patients with myopathy re-
duced amounts of mtDNAwere present in muscle biopsy speci-
mens. In contrast, muscle mtDNA content was not affected in
HIV+ patients who had not received zidovudine [13]. Depletion
ofmtDNA seemed to be reversible, and it was hypothesized that it
was due to zidovudine-induced inhibition of mtDNA replication
by DNA polymerase gamma, and was not a secondary effect of
HIV infection.
In vivo studies were performed by 31P magnetic resonance
spectra from the calf muscles of zidovudine-treated patients and
age-matched controls, at rest and during exercise [14]. The re-
covery of phosphocreatine following exercise reflects mitochon-
drial oxidative function, and was significantly delayed in treated
patients. This supported the hypothesis that the myopathy as-
sociated with chronic zidovudine treatment could result from the
inhibitory effects on mtDNA synthesis and, secondarily, on the
inhibition of mitochondrial oxidative metabolism. Concerning
other drugs of the NRTIs category, analysis of mitochondrial
function using several in vitro or ex-vivo systems or transgenic
animal models revealed that almost all NRTIs had such a sideeffect [15–17]. Drugs of the so-called D category, i.e., dideoxy-
NRTIs such as zalcitabine (ddC), didanosine (ddI), stavudine
(d4T) are the most potent inhibitors of DNA polymerase gamma,
as uniformly reported by a large number of basic and clinical
studies [17–24].
NRTIs inhibit this enzyme through four different mechanisms
encompassing their effects as: (i) mtDNA chain terminators (once
incorporated into a growing strand, DNA replication is abruptly
halted); (ii) competitive inhibitors (competing with natural nu-
cleotides to be incorporated into growing DNA chains by poly-
merase gamma); (iii) inductors of errors in the fidelity of mtDNA
replication inhibiting the exonucleolytic proofreading function
of polymerase gamma); and (iv) contributors to the decrease of
mtDNA reparatory exonuclease activity (resisting exonucleolytic
removal by exonuclease activity of polymerase gamma because
of the lack of the group 3OH in NRTIs) [25].
Several experimental systems have shown a strong correlation
between micromolar concentrations of D-NRTIs triphosphates
and decreased mtDNA or mtRNA content, decreased production
of mitochondrial polypeptides, and defective ultrastructure of the
organelle [10,11,26–47]. Inhibition of adenylate kinase, adenine
nucleotide translocator, NADH oxidase, protein glycosylation
and a “bystander” effect have also been shown, along depletion of
reduced glutathione [48–53].
At the clinical level, a diminished mitochondrial function is
supposed to be responsible for several adverse events occurring
in individuals with HIV infection who receive a therapy based
upon NRTIs. As previously observed in myocytes [13], mito-
chondrial damage is reversible also in other cell types, since
changing treatment or suspending NRTIs can result in a con-
sistent increase in mtDNA content and improvement in other mt
parameters [54,55].
Drugs of the category of PIs, whose advent has consistently
improved the survival of infected patients [56], do not seem to
have such a toxic effect. They are able to inhibit apoptosis of
both infected and uninfected Tcells, and it was hypothesized that
the mechanisms underlying this effect are associated with a
specific activity against mitochondrial modifications occurring
in the execution phase of apoptosis [57]. The protective effects
of PIs on mitochondria has been further demonstrated by using
uninfected human T lymphocytes sensitized to CD95/Fas-in-
duced physiological apoptosis via pre-exposure to HIVenvelope
protein gp120. PIswere capable of hindering earlymorphogenetic
changes bolstering T cell apoptosis, such as cell polarization and
mitochondrial hyperpolarization, and acted as boosters of mito-
chondrial defense mechanisms, including modulation of endog-
enous uncouplers [58].
In partial contrast with some of the aforementioned data,
using other cell models or other molecular biology techniques it
has been shown that mitochondria damage can be caused by the
infection with HIV as such. The intracellular distribution of
HIV-1 RNA transcripts in infected cells was studied using in
situ hybridization detected by electron microscopy and cellular
fractionation: viral RNA was found in significantly increased
amounts in mitochondria relative to the cytoplasm and nucleus,
suggesting that HIV RNA import into mitochondria can com-
promise mitochondrial function [59]. Untreated HIV+ patients
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from untreated individuals with HIV-associated myopathy or
neuropathy may have low mtDNA along with abnormalities in
mitochondrial structure or in the enzymes of the respiratory
chain [60]; these changes are similar to those provoked in vitro
by NRTIs. Declines in mtDNA in adipose tissue of untreated
individuals have also been described [61]. Changes in mtDNA
content in peripheral blood mononuclear cells (PBMCs) have
been detected when comparing healthy controls to HIV infected
individuals [62,63]. Thus, reductions in mtDNA may be caused
by HIV infection alone and precede the use of NRTIs, raising
the possibility that HIV directly, or cytokines released in res-
ponse to HIV infection or during the immune reconstitution may
injure mitochondria, potentially making them more vulnerable
to the effects of NRTIs. Since a year of treatment may increase
mtDNA and mtRNA content in PBMCs, it was suggested that
such changes may represent a restorative trend resulting from
suppression of HIV-1 infection (independent of the treatment
used) [64]. As far as HIV gene products are concerned, it has
been demonstrated that viral proteins, and in particular gp120,
can induce apoptosis in different cell types [65,66]. Tat and viral
protein R (vpr) can damage mitochondria and cause clinical
disease [67–69]. Expression of Tat may lead to cardiomyopathy
with mitochondrial destruction in mice. Vpr is able to affect the
mitochondrial permeability transition pore and may trigger cell
apoptosis through a caspase-independent mitochondrial path-
way [70]. The HIV-1 protease may also induce cell death by
processing procaspase and causing the release of cytochrome-c
[71].
Since the beginning of the studies onHIV infection, it has been
observed that the virus is able to alter the production and uti-
lization of several cytokines, from those responsible for T cell
growth such as interleukin (IL)-2 to those involved in inflam-
mation, such as IL-1, IL-6 or tumour necrosis factor (TNF)-α
[72–75]. The production of TNF-α, a pro-apoptotic cytokine that
usesmitochondria as targets [76–78], is greatly increased either in
vitro or in vivo [79–81]. TNF-α (as well as interferon-γ) can
inhibit mitochondrial respiration in smoothmuscle and other cells
[82]. Interferon-α is a pro-apoptotic cytokine whose effects are
mediated through mitochondrial cytochrome-c release and im-
paired mitochondrial DNA transcription [83]. TNF-α and inter-
feron-α are elevated in untreated HIV infection, especially in the
early phases, but may decline with therapy [84–86]. Concerning
IL-1, it has been shown that in zidovudine-induced myopathy
ragged-red fibers withmarkedmyofibrillar changes expressed IL-
1 mRNA, implying that it was produced in muscle cells. Biopsies
performed in mitochondrial myopathies of different origin re-
vealed that IL-1 expressionwasmuchweaker. This suggested that
proinflammatory and destructive effects of the studied cytokines
might be responsible for several myopathological changes ob-
served in HIV+ patients [87].
3. Mitochondria, lactic acidosis and lipodystrophy
A generalized impairment of mitochondrial function can cause
different effects that have a consistent clinical importance. Such
effects range from hyperlactatemia (that can be asymptomatic, inthe presence of efficient compensatory mechanisms) to lactic
acidosis (which is often fatal). The first description of such
syndrome in a HIV+ person taking antiretroviral drugs was that of
a 57-year-old patient, assuming zidovudine for 3 years, who
showed the concomitant occurrence of muscular and hepatic
disturbances and lactic acidosis, along with fatigue, weight, loss
and lactic acidosis [88]. The patient became confused and febrile
and died 8 days after detection of high blood lactatemia. Liver
biopsy showed diffuse macrovacuolar and microvacuolar stea-
tosis; muscle showed mitochondrial abnormalities with ragged-red
fibers and lipid droplet accumulation. Southern blot analysis
revealed depletion of mtDNA, affecting skeletal muscle and
liver tissue, suggesting that zidovudine can induce mito-
chondrial multisystem disease.
Other studies confirmed the presence of mitochondrial alte-
rations in the liver of patients with AIDS assuming zidovudine
[89]. Deletions in sperm mtDNA have been found in patients
treated with highly active antiretroviral therapy (HAART) [90],
and mtDNA content alterations in peripheral blood cells have
been observed in NRTIs-treated HIV+ patients with lactic aci-
dosis [24].
Patients taking HAART can develop lipodystrophy [6,91,92]
that has a striking similarity with multiple symmetric lipoma-
tosis (MSL) type 1, a sporadic or familial disorder characterized
by the development, during adulthood, of nonencapsulated li-
pomas around the neck and shoulders which may extend to the
back, arms and mediastinum [93,94]. The hypothesis has been
put forward that drug-induced damages to mtDNAwere able to
alter mitochondria function to a similar extent to what occurs in
MSL, where genetic defects impair the function of the orga-
nelle. It has been demonstrated that this hypothesis is correct,
sinceHIV+ patients with lipodystrophy have a diminishedmtDNA
content in adipose cells or in skeletal muscle [61,95]. A recent
study conducted on a cohort of 11 HIV+ lipodystrophic patients
showed that adipocytes collected from different anatomical
locations had alterations also in mtRNA content [96]. Three
different transcripts (ND1, CYTB and ND6 gene products)
were studied, and mtRNA content was normalized versus the
housekeeping transcript L13. All 3 gene products were signi-
ficantly reduced in HIV+ lipodystrophic patients; men and
women did not differ in a statistically significant way regarding
the levels of ND1 and ND6, whereas the opposite occurred for
CYTB.
Studies on the pathogenesis of mitochondrial alterations are
crucial to better understand themechanisms of damage and design
possible intervention or protective strategies. However, they are
quite complex because a different sensitivity to antiretroviral
drugs may exist not only among different cell types, but also
among cells of the same type in different anatomic sites [97].
Adipocytes are a source of paracrine and endocrine signals that
influence not only adipocyte biology, but also systemic me-
tabolism. HAART-induced mitochondrial damage results in an
abnormal perception of the bioenergetic status by adipocytes, thus
leading to enhancement of catalytic pathways and apoptosis in
peripheral adipose tissue, alterations in the differentiation of
brown versus white adipocytes, and the release of hormonal
signals that lead to systemic metabolic disturbances [98–100].
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to lipolytic and lipogenic stimuli, in adipocyte apoptosis, and in
the potential for preadipocyte replication and differentiation [101].
Furthermore, besides the obvious problems related to the
collection of the biological material, another limitation exists,
i.e., that related to the technology used to measure different mito-
chondrial parameters, that can account, at least in part, for the
heterogeneity of the results present in the literature.
4. Correlations between in vitro studies and patient's
treatment
Several molecular and cellular techniques and different in
vitro models are currently available to analyze mitochondria,
and a variety of methods have been used by researchers in the
field of HIV to investigate cells treated with different com-
pounds, or cells collected from patients taking different thera-
peutic regimens [90,95–100,102–106].
Studies on the effects of antiretroviral drugs on mitochondria
in cell lines are relatively easy, but it is necessary to pay attention
to potential discrepancies between data obtained in vitro or ex
vivo, namely from continuously growing, cultured cells (of
tumour origin) treated with a given drug, and data obtained from
a patient treated with the same drug. The evaluation of drug-
induced mitochondrial damages in patients is extremely com-
plex because of a variety of problems that include, among others:
(a) The possibility to study adequate and representative cells.
Liver is clearly a main target for drugs that have mitochondrial
toxicity, and its dysfunction is likely the main etiological factor
for the onset of lactic acidosis. It is logical that the best cellular
model for the ex vivo detection of the hepatotoxicity of a drug
comes from the liver itself, but biopsies are not always feasible
either for ethical or practical reasons. It is instead relatively easy
to obtain blood from a patient, but not always blood cells can
provide useful information. As an example, there is growing
interest in the evaluation of the mtDNA copy number in white
blood cells from patients treated with different antiretrovirals, as
a possible marker of drug toxicity. The first study on mtDNA
content in peripheral blood lymphocytes analyzed mitochondria
function and apoptosis in cells of HIV-infected children, with or
without lipodystrophy, who were receiving HAART [18]. A
variety of parameters were investigated, but no main changes
were detected in lymphocytes from children with lipodystrophy,
suggesting that normal mitochondrial function and tendency to
undergo apoptosis were present in these cells. The use of pe-
zripheral blood cells is in fact more complex than what was
thought, as shown by the presence of contrasting data regarding
the effects of antiretroviral therapy on mtDNA. It has to be
considered that if cells derived from peripheral blood using
standard isolation methods are used, platelet contamination must
be accounted for [107]. In peripheral blood and buffy coat sam-
ples, platelets are considerably over-represented compared to
leukocytes. Platelets contain mitochondria (and thus mtDNA
and also mtRNA) but not a nucleus (and thus, they have no
nuclear DNA). Usually mtDNA is quantify as a ratio versus
nuclear DNA, and thus, if platelets are not accurately removed,
changes in the content of mtDNA in a given cell populationcould be due to several causes, including variations in platelet
quantity, which may be affected not only by antiretroviral the-
rapy but also by sample processing or storage. Platelet removal
has to be readily performed and cells of interest (e.g., lym-
phocytes, monocytes) have preferably to be purified bymagnetic
sorting or other systems.
Also, adipocytes are extremely useful to investigate drug-
related damages to mtDNA, especially when studies on lipo-
dystrophy are concerned. In the first pivotal study, mtDNA con-
tent of subcutaneous fat tissue from the neck, abdomen and thigh
was measured [61]. A decrease in mtDNA content was found in
HAART-treated HIV+ patients with peripheral fat wasting in
comparison with HIV+ patients without lipodystrophy but with a
similar treatment history; HIV+ patients naive to antiretroviral
therapy and healthy controls had similar amounts of mtDNA,
suggesting that lipodystrophy with peripheral fat wasting follow-
ing treatment withNRTIs-containingHAART is associatedwith a
decrease in subcutaneous adipose tissue mtDNA content.
(b) The possibility to obtain sufficient amounts of biological
material. Some assays, especially those based upon molecular
biology techniques and PCR, require a relative small amount of
material. Other assays, for example, those regarding functional
analysis on cultured cells, require much more material, and are
often difficult to perform in biological material collected from
human beings.
(c) The clinical status and other therapies assumed by the
patient at the moment of cell collection. A variety of functional
assays are extremely sensitive to parameters that are linked to
the status of the host. Thus, several situations can influence the
result of a test, including, among others, the presence of conco-
mitant infections, the adherence to therapy, the intake of diffe-
rent drugs or biologically active molecule. More than 70% of
HIV+ patients had used complementary and alternative medi-
cine (CAM) therapies before the diagnosis of HIV infection;
after diagnosis, percentages increased of another 13%; more
than 90% of HIV patients had used at least one CAM therapy
sometime in their lives [108,109]. It is poorly known if and how
CAM can affect the success of HAART, and there is an almost
complete ignorance of eventual serious complications of their
association. For example, relevant interactions exist between
antiretroviral drugs and Hypericum perforatum (known as St.
John's Worth, SJV), a natural antidepressant with more than
2.7 million prescriptions every year. SJV may influence the
metabolism of coadministered drugs: administration of SJV
with the PI indinavir produces an 81% reduction in drug plasma
concentration, either altering the expression of the multidrug
resistance P-glycoprotein 1, or inducing expression of the he-
patic enzyme CYP3A4 [110]. As a result, the efficacy of anti-
retroviral therapy is seriously compromised, and the production
of HIV is no longer inhibited.
(d) To use the right assay in a correct manner. Actually, an
enormous number of tests have been standardized, including those
that require sophisticated technologies or instruments. However, a
paradoxical side effect exists that is related to the relative simplicity
of a given assay, i.e., the fact that several researchers could use an
assay without the adequate scientific qualification. The conclusion
that, for example, a given drug assumed by a group of patients can
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than another is difficult to accept. This is when, for example, data
show that the percentage of cells with depolarized mitochondria
(analyzed by flow cytometry) increases from 2% (in controls) to
3% (in treated patients) [111]. More expertise in the analysis and
interpretation of cytofluorimetric data would be necessary.
(e) Last, but not least, the possibility to compare the data
obtained in patients with those from healthy donors. This is the
crucial aspect: clearly, it is quite easy to collect blood from a
healthy individual, but obtaining liver cells, fibroblasts or adi-
pocytes may be a major problem.
In conclusion, several aspects have to be considered in studies
on the mitochondrial toxicity of antiretroviral drugs. The extra-
polation to the clinical practice is often complicated by the
aforementioned causes. However, it can be predicted that, in a
relatively near future, the development of new experimental
models and strategies will improve the possibility to take ad-
vantage from these studies.
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